What Nortec Quimica does

Nortec Química S.A. (B3: NORT3) is Brazil's only and Latin America's largest manufacturer of Active Pharmaceutical Ingredients (IFAs), producing more than 50 APIs using proprietary chemical synthesis processes developed in partnership with Brazilian research institutions including UFRJ, Fiocruz, and COPPETEC. Founded in 1985 in Duque de Caxias (Rio de Janeiro) as a subsidiary of NORQUISA, the company operates from a 38,000m² site with 12,962m² of built area comprising five multi-purpose synthesis units with 116m³ of reactor capacity producing 340 tonnes/year (expandable to 500 tonnes/year). Its portfolio covers local anesthetics, antiretrovirals, benzodiazepines, and treatments for neglected diseases including benznidazol (the world's only producer) and propylthiouracil. Manufacturing is regulated under ANVISA cBPF (since 2002) and FDA (since 2016), with Drug Master Files registered globally and CEP processes underway.

Nortec generates revenue through B2B sales of APIs to pharmaceutical manufacturers (brand, generic, and similar), supplemented by supply to Brazil's public health system (SUS) via Ministry of Health Partnership for Productive Development (PDP) programs with Fiocruz/Farmanguinhos and LQFEx. Distribution reaches 248+ customers across 46 countries. The company has expanded its commercial surface through a CDMO (Contract Development and Manufacturing Organization) platform offering integrated services from IND-enabling work through commercial production, and through international licensing — most notably the 2022 MPP/Pfizer sublicense for nirmatrelvir production covering ~95 low- and middle-income countries. Capital structure includes a 20% BNDESPar equity stake (held since 2002) alongside listed common shares.

The company's go-to-market combines enterprise field sales targeting pharmaceutical manufacturers with participation in global industry events (CPhI Worldwide, FCE Pharma) and direct engagement with public-sector counterparties. Pricing is negotiated bilaterally under multi-year supply contracts; no public pricing exists. Recent strategic activity has emphasized internationalization (2022 Arab-Brazilian Chamber membership; 2025 Brazil–China bilateral agreement), neglected-disease partnerships (2023 Fiocruz benznidazol expansion), and ESG positioning (100% renewable energy certification in 2022, 805 tonnes CO₂ reduction).

Name

Nortec Quimica

Legal name

Nortec Química S.A.

Website

https://nortecquimica.com.br

Company type

Public

Founded year

1985

Operating status

Operating

Headcount range

251–500 employees

Short description

Nortec Química (B3: NORT3) is Latin America's largest Active Pharmaceutical Ingredient (API) manufacturer and the only one in Brazil, producing 50+ IFAs from its Duque de Caxias facility for global pharmaceutical manufacturers, Brazilian generic drugmakers, and the SUS public health system.

Ownership category

akta.pro rank

Product category

Active Pharmaceutical Ingredients (API) Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Small-Molecule API & Intermediates CDMO (HLAGABAA)

akta.pro secondary industries

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

Keywords

• Active pharmaceutical ingredients
• API manufacturing
• Pharmaceutical chemistry
• Generic medicine inputs
• Contract drug manufacturing

Headquarters

HQ city

Duque De Caxias

HQ country

Brazil

HQ region

Latin America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Active Pharmaceutical Ingredient (API) Sales: B2B sales of pharmaceutical active ingredients to pharmaceutical manufacturers for brand, generic, and similar medications. Revenue generated from manufacturing and supplying APIs for various therapeutic categories including anesthetics, antiretrovirals, anxiolytics, and drugs for neglected diseases.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Nortec Quimica manufactures Active Pharmaceutical Ingredients (IFAs/APIs) from petroleum derivatives (benzene, toluene, xylenes), producing over 50 APIs including local anesthetics, antiretrovirals, benzodiazepines, and drugs for neglected diseases such as Chagas disease treatment. The company operates a full-service CDMO (Contract Development and Manufacturing Organization) platform spanning IND-Enabling through commercial production with up to 500 tonnes/year capacity, supporting both domestic and international pharmaceutical manufacturers as well as Brazil's public health system (SUS).

Product overview

Nortec Quimica operates as a pharmaceutical chemistry company manufacturing Active Pharmaceutical Ingredients (IFAs) with three main product lines: Regular Production (over 50 commercial IFAs including local anesthetics, antiretrovirals, benzodiazepines, and drugs for neglected diseases), Strategic Pipeline (development-stage IFAs), and a CDMO Platform for contract development and manufacturing. The company also provides integrated R&D and Quality Control services. Their portfolio covers local anesthetics (Bupivacaine, Lidocaine, Articaine), anti-HIV drugs (Dolutegravir, Efavirenz, Lamivudine), benzodiazepines (Midazolam, Clonazepam), and specialty drugs like Benznidazole for Chagas disease and Mycophenolate for transplants.

Differentiator

Problem solved

Functional benefit

Products and services

• Active Pharmaceutical Ingredients (IFAs) - Regular Production Core manufacturing of over 50 Active Pharmaceutical Ingredients (IFAs/APIs) including local anesthetics (Bupivacaine, Lidocaine, Articaine, Mepivacaine, Prilocaine), anti-HIV antiretrovirals (Dolutegravir, Efavirenz, Lamivudine, Zidovudine, Tenofovir), benzodiazepines (Midazolam, Clonazepam, Diazepam), Olanzapine, Escetamine, Chlorhexidine, and drugs for neglected diseases, for sale to brand, generic, and similar medication manufacturers.
• Strategic Pipeline (Development-Stage APIs) Development-stage Active Pharmaceutical Ingredients in the strategic pipeline, representing future product offerings and expansion of the company's IFA portfolio with new molecules progressing toward commercial production.
• CDMO Platform (Contract Development and Manufacturing Organization) Full-service CDMO platform offering integrated API development from idea to commercial production, including IND-Enabling services, analytical development, process development, scalable synthesis, pilot and commercial manufacturing with up to 500 tonnes/year capacity, and regulatory support for Drug Master Files (DMFs) and CADIFAs, for both domestic Brazilian and international pharmaceutical customers.
• Research & Development Services Scientific research and development services staffed by chemists, pharmacists, masters, and PhDs, developing new molecular entities (NMEs) with proprietary Brazilian technology in partnership with national research centers including Fiocruz, UFRJ, and IQ-UFRJ.
• Quality Control & Analytical Testing Quality assurance and control services including analytical method development and validation, stability studies per climatic zones, and compliance with US and European Pharmacopeia standards, delivered via chromatographs managed by software meeting FDA 21 CFR Part 11 requirements.

Quantifiable outcome

• Only 5% of Brazil's API needs are met domestically; government target is 70% self-sufficiency by 2033
• +2 more outcomes

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Fiocruz/FarmanguinhoscoreStrategic or Co-development Partner · 2 June 2023Technical and scientific cooperation agreement for development of improved benznidazol production process for Chagas disease treatment. New synthetic method developed by Fiocruz will be scaled up through Nortec's R&D and production capabilities.
• Laboratório Químico Farmacêutico do Exército (LQFEx)minorStrategic or Co-development Partner · 2 June 2023Recognition as 'Empresa Amiga' (Friendly Company) for participation in Mycophenolate Sodium PDP for transplant patients. Technology transfer from EMS with Nortec supplying national API.
• Câmara de Comércio Árabe-BrasileiraminorGTM or Marketing Partner · 28 September 2022Membership in Arab-Brazilian Chamber of Commerce since 2022 as part of internationalization and expansion strategy to connect with Arab markets.
• The Medicines Patent Pool (MPP)coreStrategic or Co-development Partner · 21 March 2022Licensing agreement from Pfizer through MPP for production of nirmatrelvir API for COVID-19 oral treatment, enabling supply to approximately 53% of world's population in 95 low and medium income countries.
• FiocruzcoreStrategic or Co-development Partner · 1 January 1986Initial technology cooperation agreement signed January 17, 1986 between Fiocruz and Nortec for establishing domestic pharmaceutical API manufacturing capability, originating from cooperation between Norquisa and Fiocruz under general Ernesto Geisel.
• Norquisa (Nordeste Química SA)coreOthers · 1 January 1985Original parent company that created Nortec-Nordeste Química Developments Tecnológicos Ltda as subsidiary in December 1985, the embryonic cell of current Nortec Química S.A.
• COPPETEC/UFRJcoreTechnology or Integration · 1 January 1980Long-standing technology partnership since the 1980s for effluent treatment system development. Joint project includes anoxic, aerobic, and physico-chemical treatment stages achieving stabilized biomass and environmental compliance.

Scale indicators8 records

Recent moves12 records

Expansion highlights6 records

Direct peers

• Cristália Produtos Químicos Farmacêuticos: Brazilian pharmaceutical-chemical company producing APIs and finished pharmaceutical products, including controlled substances and hospital medicines. Comparable as a domestic LatAm API/pharma manufacturer with similar regulatory footprint, product categories (anesthetics, benzodiazepines), and reliance on public-sector procurement.
• Aché Laboratórios: Major Brazilian pharmaceutical manufacturer and a qualified Nortec customer. Comparable as a domestic pharmaceutical player operating in the same regulatory and PDP ecosystem, with similar exposure to SUS tenders and brand/generic formulation in Brazil.
• Cambrex Corporation: US-based small-molecule API CDMO with FDA-inspected facilities and a comparable service platform spanning process development through commercial supply. Comparable as a regulated small-molecule CDMO competing for the same global pharma outsourcing wallet.
• Siegfried Holding: Swiss-listed CDMO specializing in small-molecule API and finished dose manufacturing with FDA/EMA approvals. Comparable as a regulated, multi-customer API CDMO with a similar technology platform (multi-purpose synthesis units) and customer mix across branded and generic pharma.
• EMS Pharma: Brazil's leading generics manufacturer and a Nortec customer that received BNDES financing for capacity expansion. Comparable as a large domestic generic-drug player dependent on local API supply, sharing the same government-driven procurement and self-sufficiency dynamics.
• Divi's Laboratories: Indian-listed global leader in small-molecule API and intermediates manufacturing with proprietary process development. Comparable as a pure-play, small-molecule API manufacturer serving global generics and CDMO customers with FDA-approved facilities.

Broad incumbents

• Eurofarma Laboratórios: Largest Brazilian-owned pharmaceutical company with vertically integrated API and finished dose manufacturing. Comparable as a domestic LatAm pharma champion pursuing API self-sufficiency, though Eurofarma's portfolio is much broader and brand-led rather than API-focused.
• Dr. Reddy's Laboratories: Indian global pharmaceutical company with significant API manufacturing and CDMO services. Comparable as a regulated, globally distributed small-molecule API and CDMO provider, and one of the import competitors reshaping the competitive landscape for Nortec in Latin America.
• Aurobindo Pharma: Large Indian vertically integrated API + generics manufacturer. Comparable as one of the low-cost Asian API exporters that defines the competitive backdrop for Nortec in Brazil, and a benchmark for the scale and cost structure Nortec must offset via regulatory and proximity advantages.

Regional players

• Biolab Sanus Farmacêutica: Brazilian pharmaceutical company with branded and generic portfolios, operating in the same SUS and PDP environment. Comparable as a domestic pharma peer that both competes for and consumes local API supply, with similar exposure to Brazilian regulatory and pricing dynamics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInbr.linkedin.com/company/nortec-quimica-s-a-

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nortec Quimica